Harsha Ramchandani, MD
Internal Medicine · Fremont
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 3 carriers
- Offices
- 6
Offices
6 locations · Bay Area Community Health · 106 clinicians in this group
Hospitals listed: Highland Hospital. That is not proof they admit you there this week.
Plans that list them
14 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ramchandani’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A123183 · Current
Licensed to practise in California · since 2012 · expires 2028-08-31 · Barkatulla Vishwavidyalaya University, Gandhi Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Highland HospitalOakland, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Alameda Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.568, Oct 2024 – Sep 2025
See every measure and the patient survey for Highland Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 5 the same, 1 worse of 6 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.568 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.99) · 487 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.7 to 1.42) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.35 (145.43 to 251.26) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 83 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.3 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 68 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 1,143 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.38) · 4,370 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,344 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.54 (0.29 to 4.79) · 689 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.07 (0.37 to 3.78) · 165 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.91 (0.34 to 3.48) · 681 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.62 (2.72 to 20.53) · 179 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.44 (1.37 to 9.5) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.97 (0.49 to 3.45) · 126 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.76 (0.07 to 1.44) · 3,387 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.519 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.682 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 51 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 184 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 141.8 · 59 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 27.6 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 35.3 · 253 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 243 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.2 to 7.7) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (9.7 to 18.5) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.4 (10.8 to 19.4) · 355 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 84 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,960 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
Medicaid work
$2,243,899 in 2024
Medicaid paid $2,243,899 for 22,336 billed services this clinician did in 2024, up to 589 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 8,917 | $2,212,425 |
| Short return visit (20+ min) | 7,105 | $14,561 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years | 150 | $4,817 |
| Hemoglobin A1C level | 560 | $2,637 |
| Return visit (30+ min) | 2,152 | $1,697 |
| Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule, for intramuscular use | 45 | $1,444 |
| Short return visit | 989 | $1,389 |
| Blood glucose (sugar) level | 505 | $1,128 |
| Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use | 25 | $1,120 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 46 | $758 |
| New patient visit (30+ min) | 131 | $602 |
| Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 172 | $482 |
| 2024 | 22,336 | 28 | 589 | $2,243,899 |
| 2023 | 13,216 | 16 | 447 | $1,489,671 |
| 2022 | 7,208 | 14 | 331 | $747,581 |
| 2021 | 10,190 | 17 | 363 | $1,028,362 |
| 2020 | 11,942 | 12 | 228 | $1,038,965 |
| 2019 | 4,273 | 19 | 129 | $425,555 |
| 2018 | 5,646 | 15 | 152 | $610,344 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 6,191 | $1,480,559 |
| Short return visit (20+ min) | 4,630 | $4,946 |
| Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use | 15 | $1,346 |
| Return visit (30+ min) | 1,170 | $1,159 |
| Short return visit | 503 | $749 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years | 33 | $583 |
| Hemoglobin A1C level | 40 | $177 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 36 | $64 |
| Blood glucose (sugar) level | 25 | $56 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 313 | $31 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 70 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 61 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 3,389 | $732,171 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose | 119 | $7,784 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose | 36 | $1,953 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose | 38 | $1,873 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose | 26 | $1,634 |
| Short return visit (20+ min) | 2,124 | $1,133 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose | 12 | $804 |
| Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use | 28 | $112 |
| Short return visit | 612 | $74 |
| Return visit (30+ min) | 567 | $38 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 199 | $5 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) | 28 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 4,416 | $939,831 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose | 418 | $25,845 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose | 402 | $24,754 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose | 279 | $14,702 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose | 156 | $8,501 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose | 127 | $5,837 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose | 101 | $5,569 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage; single dose | 52 | $3,200 |
| Short return visit (20+ min) | 3,205 | $120 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 44 | $5 |
| Hemoglobin; by copper sulfate method, non-automated | 47 | $0 |
| Hemoglobin A1C level | 18 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 4,791 | $1,031,053 |
| Short return visit (20+ min) | 4,914 | $4,087 |
| Return visit (30+ min) | 804 | $1,492 |
| Short return visit | 776 | $1,122 |
| Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes | 154 | $786 |
| Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes | 143 | $392 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 151 | $33 |
| Blood glucose (sugar) level | 70 | $0 |
| Hemoglobin; by copper sulfate method, non-automated | 17 | $0 |
| Hemoglobin A1C level | 89 | $0 |
| OFFICE/OUTPATIENT VISIT NEW | 12 | $0 |
| New patient visit (30+ min) | 21 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 1,953 | $423,502 |
| Short return visit (20+ min) | 780 | $603 |
| Prenatal care, at-risk enhanced service; education | 179 | $505 |
| Return visit (30+ min) | 389 | $450 |
| URINE PREGNANCY TEST | 161 | $109 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 30 | $90 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 138 | $60 |
| Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes | 16 | $59 |
| Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use | 14 | $45 |
| Health and behavior assessment (eg, health-focused clinical interview, behavioral observations, psychophysiological monitoring, health-oriented questionnaires), each 15 minutes face-to-face with the patient; re-assessment | 42 | $42 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 205 | $34 |
| Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use | 15 | $33 |
2018
| Clinic visit/encounter, all-inclusive | 2,994 | $604,686 |
| Short return visit (20+ min) | 820 | $1,285 |
| Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes | 105 | $1,226 |
| Prenatal care, at-risk enhanced service; education | 275 | $833 |
| Return visit (30+ min) | 378 | $696 |
| Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes | 79 | $431 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 265 | $416 |
| URINE PREGNANCY TEST | 175 | $189 |
| Health and behavior assessment (eg, health-focused clinical interview, behavioral observations, psychophysiological monitoring, health-oriented questionnaires), each 15 minutes face-to-face with the patient; re-assessment | 78 | $177 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 113 | $158 |
| Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use | 54 | $108 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 96 | $103 |
Drugs they prescribed that Part D paid
$56,898
Pharmacies billed $56,898 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (17 of 498) in 2024. Above the middle of the specialty; the typical internal medicine clinician is at 1%.
422 generic and fewer than 11 brand-name prescriptions · $56,898 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 20 | $18,303 | $915 |
| Buprenorphine-Naloxone | 41 | $10,819 | $264 |
| Levothyroxine | 21 | $208 | $10 |
| Simvastatin | 22 | $125 | $6 |
| Omeprazole | 16 | $121 | $8 |
See all 12 drugs
| Ozempic | 20 | $18,303 | $915 |
| Buprenorphine-Naloxone | 41 | $10,819 | $264 |
| Levothyroxine | 21 | $208 | $10 |
| Simvastatin | 22 | $125 | $6 |
| Omeprazole | 16 | $121 | $8 |
| Amlodipine Besylate | 38 | $108 | $3 |
| Atorvastatin | 22 | $94 | $4 |
| Losartan | 15 | $72 | $5 |
| Lisinopril | 21 | $69 | $3 |
| Hydrocodone-Acetaminophen | 15 | $61 | $4 |
| Metformin | 22 | $59 | $3 |
| Metoprolol | 12 | $17 | $1 |
Year by year
| 2024 | 498 | 53 | 3% (17) | None | $56,898 |
| 2023 | 371 | 69 | 3% (11) | 19% | $61,914 |
| 2022 | 330 | 40 | None | 18% | $48,644 |
| 2021 | 620 | 78 | 3% (17) | 13% | $50,904 |
| 2020 | 1,306 | 108 | 2% (24) | 14% | $93,514 |
| 2019 | 1,389 | 120 | 2% (27) | 15% | $63,901 |
| 2018 | 1,898 | 130 | 2% (30) | 9% | $154,689 |
| 2017 | 1,561 | 130 | 1% (18) | 8% | $40,493 |
| 2016 | 997 | 93 | None | 7% | $31,153 |
| 2015 | 688 | 110 | 3% (23) | None | $37,485 |
| 2014 | 1,003 | 121 | 4% (44) | 23% | $54,088 |
| 2013 | 718 | 98 | 5% (35) | 20% | $39,097 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Ozempic | 12 | $12,446 | $1,037 |
| Atorvastatin | 20 | $618 | $31 |
| Famotidine | 13 | $600 | $46 |
| Losartan | 14 | $589 | $42 |
| Lisinopril | 18 | $388 | $22 |
| Simvastatin | 15 | $292 | $19 |
| Levothyroxine | 12 | $291 | $24 |
| Amlodipine Besylate | 15 | $270 | $18 |
| Gabapentin | 14 | $248 | $18 |
| Metformin | 14 | $216 | $15 |
2022: 5 drugs
| Alcohol Pads | 12 | $916 | $76 |
| Atorvastatin | 18 | $574 | $32 |
| Famotidine | 12 | $508 | $42 |
| Losartan | 15 | $353 | $24 |
| Simvastatin | 17 | $209 | $12 |
2021: 16 drugs
| Lantus Solostar | 18 | $4,906 | $273 |
| Atorvastatin | 36 | $912 | $25 |
| Alcohol Pads | 14 | $807 | $58 |
| Albuterol Sulfate Hfa | 14 | $732 | $52 |
| Losartan | 32 | $504 | $16 |
| Levothyroxine | 21 | $454 | $22 |
| Famotidine | 13 | $346 | $27 |
| Gabapentin | 35 | $335 | $10 |
| Simvastatin | 26 | $236 | $9 |
| Amlodipine Besylate | 24 | $219 | $9 |
| Metformin | 31 | $212 | $7 |
| Lisinopril | 17 | $150 | $9 |
| Alendronate | 13 | $122 | $9 |
| Hydrochlorothiazide | 19 | $112 | $6 |
| Buspirone | 13 | $85 | $7 |
| Metoprolol | 12 | $73 | $6 |
2020: 35 drugs
| Januvia | 14 | $16,763 | $1,197 |
| Trulicity | 13 | $13,989 | $1,076 |
| Lantus Solostar | 18 | $5,576 | $310 |
| Basaglar Kwikpen U-100 | 15 | $4,594 | $306 |
| Fenofibrate | 17 | $1,758 | $103 |
| Alcohol Pads | 16 | $1,671 | $104 |
| Levothyroxine | 36 | $905 | $25 |
| Atorvastatin | 61 | $778 | $13 |
| Losartan | 71 | $747 | $11 |
| Losartan-Hydrochlorothiazide | 14 | $737 | $53 |
| Ultra-Fine Mini Pen Needle | 13 | $636 | $49 |
| Metformin | 82 | $501 | $6 |
| Gabapentin | 55 | $445 | $8 |
| Simvastatin | 62 | $420 | $7 |
| Glipizide Er | 25 | $385 | $15 |
| Amlodipine Besylate | 70 | $370 | $5 |
| Metoprolol | 18 | $348 | $19 |
| Hydrochlorothiazide | 59 | $292 | $5 |
| Pantoprazole | 15 | $279 | $19 |
| Omeprazole | 35 | $277 | $8 |
| Diclofenac | 13 | $237 | $18 |
| Famotidine | 15 | $225 | $15 |
| Lisinopril | 39 | $195 | $5 |
| Alendronate | 15 | $174 | $12 |
| Trazodone | 20 | $170 | $8 |
| Hydralazine | 19 | $163 | $9 |
| Metoprolol | 11 | $157 | $14 |
| Buspirone | 14 | $151 | $11 |
| Metformin Hcl Er | 11 | $150 | $14 |
| Glipizide | 16 | $144 | $9 |
| Quetiapine | 11 | $126 | $11 |
| Atenolol | 19 | $123 | $6 |
| Clonidine | 15 | $101 | $7 |
| Oxycodone | 12 | $62 | $5 |
| Paroxetine | 12 | $61 | $5 |
2019: 31 drugs
| Basaglar Kwikpen U-100 | 23 | $4,694 | $204 |
| Lantus Solostar | 13 | $3,002 | $231 |
| Atorvastatin | 73 | $786 | $11 |
| Amlodipine Besylate | 101 | $648 | $6 |
| Fenofibrate | 14 | $640 | $46 |
| Gabapentin | 57 | $607 | $11 |
| Simvastatin | 71 | $565 | $8 |
| Losartan | 79 | $541 | $7 |
| Levothyroxine | 34 | $488 | $14 |
| Glipizide Er | 29 | $413 | $14 |
| Metformin | 66 | $348 | $5 |
| Losartan-Hydrochlorothiazide | 25 | $332 | $13 |
| Omeprazole | 32 | $294 | $9 |
| Atenolol | 35 | $277 | $8 |
| Diclofenac | 14 | $270 | $19 |
| Lisinopril | 42 | $241 | $6 |
| Latanoprost | 17 | $232 | $14 |
| Hydralazine | 19 | $222 | $12 |
| Pravastatin | 13 | $220 | $17 |
| Hydrochlorothiazide | 41 | $219 | $5 |
| Metformin Hcl Er | 17 | $198 | $12 |
| Nabumetone | 11 | $171 | $16 |
| Fluticasone Propionate | 13 | $164 | $13 |
| Carvedilol | 20 | $144 | $7 |
| Quetiapine | 13 | $127 | $10 |
| Lisinopril-Hydrochlorothiazide | 16 | $97 | $6 |
| Glimepiride | 11 | $89 | $8 |
| Glipizide | 15 | $76 | $5 |
| Hydrocodone-Acetaminophen | 11 | $72 | $7 |
| Clonidine | 13 | $67 | $5 |
| Oxycodone | 11 | $47 | $4 |
2018: 45 drugs
| Lantus | 14 | $4,741 | $339 |
| Levemir | 11 | $3,849 | $350 |
| Ventolin Hfa | 19 | $1,242 | $65 |
| Gabapentin | 88 | $1,153 | $13 |
| Simvastatin | 144 | $816 | $6 |
| Losartan | 124 | $811 | $7 |
| Amlodipine Besylate | 119 | $687 | $6 |
| Fenofibrate | 20 | $664 | $33 |
| Ultra-Fine Mini Pen Needle | 15 | $655 | $44 |
| Atorvastatin | 68 | $620 | $9 |
| Metformin | 119 | $543 | $5 |
| Metoprolol | 29 | $479 | $17 |
| Hydroxychloroquine Sulfate | 11 | $465 | $42 |
| Glipizide Er | 24 | $374 | $16 |
| Diclofenac | 13 | $363 | $28 |
| Cyclobenzaprine | 13 | $349 | $27 |
| Losartan-Hydrochlorothiazide | 50 | $348 | $7 |
| Phenobarbital | 12 | $345 | $29 |
| Memantine | 11 | $334 | $30 |
| Hydrocodone-Acetaminophen | 20 | $292 | $15 |
| Pravastatin | 20 | $289 | $14 |
| Lisinopril | 78 | $285 | $4 |
| Hydralazine | 26 | $256 | $10 |
| Omeprazole | 39 | $255 | $7 |
| Levothyroxine | 19 | $226 | $12 |
| Atenolol | 39 | $223 | $6 |
| Trazodone | 31 | $210 | $7 |
| Hydrochlorothiazide | 47 | $206 | $4 |
| Metoprolol | 44 | $188 | $4 |
| Famotidine | 11 | $170 | $15 |
| Fluticasone Propionate | 17 | $167 | $10 |
| Furosemide | 30 | $157 | $5 |
| Donepezil | 11 | $146 | $13 |
| Tamsulosin | 14 | $145 | $10 |
| Hydroxyzine | 17 | $126 | $7 |
| Meloxicam | 21 | $108 | $5 |
| Glimepiride | 14 | $103 | $7 |
| Tizanidine | 11 | $84 | $8 |
| Metformin Hcl Er | 25 | $82 | $3 |
| Carvedilol | 13 | $82 | $6 |
| Lovastatin | 14 | $78 | $6 |
| Sertraline | 23 | $76 | $3 |
| Paroxetine | 16 | $50 | $3 |
| Glipizide | 18 | $39 | $2 |
| Lisinopril-Hydrochlorothiazide | 13 | $19 | $1 |
2017: 38 drugs
| Lantus Solostar | 11 | $4,045 | $368 |
| Humulin 70-30 | 11 | $3,175 | $289 |
| Pataday | 13 | $2,196 | $169 |
| Atorvastatin | 68 | $674 | $10 |
| Amlodipine Besylate | 116 | $593 | $5 |
| Simvastatin | 128 | $548 | $4 |
| Metoprolol | 30 | $498 | $17 |
| Memantine | 12 | $480 | $40 |
| Losartan | 93 | $420 | $5 |
| Fenofibrate | 18 | $368 | $20 |
| Levothyroxine | 22 | $360 | $16 |
| Omeprazole | 49 | $323 | $7 |
| Metformin | 91 | $305 | $3 |
| Lisinopril | 73 | $287 | $4 |
| Doxazosin Mesylate | 13 | $218 | $17 |
| Olanzapine | 14 | $213 | $15 |
| Gabapentin | 41 | $210 | $5 |
| Losartan-Hydrochlorothiazide | 41 | $205 | $5 |
| Atenolol | 56 | $181 | $3 |
| Donepezil | 12 | $180 | $15 |
| Hydralazine | 21 | $176 | $8 |
| Hydrochlorothiazide | 49 | $161 | $3 |
| Fluticasone Propionate | 16 | $158 | $10 |
| Glipizide Er | 22 | $148 | $7 |
| Trazodone | 29 | $132 | $5 |
| Pravastatin | 13 | $96 | $7 |
| Glipizide | 30 | $95 | $3 |
| Metformin Hcl Er | 15 | $95 | $6 |
| Cyclobenzaprine | 14 | $88 | $6 |
| Metoprolol | 22 | $73 | $3 |
| Lovastatin | 12 | $71 | $6 |
| Meloxicam | 23 | $65 | $3 |
| Paroxetine | 20 | $54 | $3 |
| Furosemide | 16 | $39 | $2 |
| Ibuprofen | 11 | $35 | $3 |
| Lisinopril-Hydrochlorothiazide | 13 | $35 | $3 |
| Sertraline | 11 | $31 | $3 |
| Alendronate | 12 | $12 | $1 |
2016: 25 drugs
| Simvastatin | 92 | $488 | $5 |
| Atorvastatin | 41 | $438 | $11 |
| Losartan | 58 | $387 | $7 |
| Amlodipine Besylate | 71 | $359 | $5 |
| Gabapentin | 35 | $259 | $7 |
| Lisinopril | 65 | $252 | $4 |
| Metoprolol | 17 | $244 | $14 |
| Metformin | 58 | $242 | $4 |
| Omeprazole | 25 | $213 | $9 |
| Quetiapine | 12 | $172 | $14 |
| Atenolol | 23 | $163 | $7 |
| Losartan-Hydrochlorothiazide | 25 | $156 | $6 |
| Lovastatin | 26 | $151 | $6 |
| Paroxetine | 19 | $142 | $7 |
| Trazodone | 25 | $131 | $5 |
| Pravastatin | 11 | $130 | $12 |
| Hydrochlorothiazide | 33 | $124 | $4 |
| Glipizide Er | 12 | $109 | $9 |
| Levothyroxine | 16 | $90 | $6 |
| Gemfibrozil | 11 | $85 | $8 |
| Glipizide | 13 | $62 | $5 |
| Zolpidem | 11 | $57 | $5 |
| Ibuprofen | 11 | $40 | $4 |
| Metoprolol | 16 | $37 | $2 |
| Alendronate | 12 | $34 | $3 |
2015: 20 drugs
| Proair Hfa | 12 | $636 | $53 |
| Levothyroxine | 29 | $554 | $19 |
| Metoprolol | 12 | $428 | $36 |
| Atorvastatin | 27 | $372 | $14 |
| Donepezil | 14 | $297 | $21 |
| Baclofen | 11 | $285 | $26 |
| Metformin | 24 | $215 | $9 |
| Amlodipine Besylate | 24 | $212 | $9 |
| Gabapentin | 15 | $196 | $13 |
| Lisinopril | 30 | $194 | $6 |
| Losartan | 15 | $179 | $12 |
| Simvastatin | 22 | $171 | $8 |
| Omeprazole | 14 | $161 | $11 |
| Fluticasone Propionate | 13 | $151 | $12 |
| Lovastatin | 15 | $146 | $10 |
| Hydrochlorothiazide | 27 | $133 | $5 |
| Sertraline | 18 | $131 | $7 |
| Atenolol | 11 | $89 | $8 |
| Furosemide | 22 | $80 | $4 |
| Losartan-Hydrochlorothiazide | 11 | $65 | $6 |
2014: 25 drugs
| Lyrica | 12 | $3,053 | $254 |
| Zetia | 11 | $2,115 | $192 |
| Gabapentin | 11 | $1,388 | $126 |
| Proair Hfa | 22 | $1,262 | $57 |
| Atorvastatin | 54 | $1,044 | $19 |
| Metoprolol | 19 | $955 | $50 |
| Potassium Chloride | 18 | $735 | $41 |
| Levothyroxine | 36 | $623 | $17 |
| Fluticasone Propionate | 30 | $538 | $18 |
| Venlafaxine Hcl Er | 12 | $403 | $34 |
| Lisinopril | 55 | $346 | $6 |
| Amlodipine Besylate | 38 | $303 | $8 |
| Hydrocodone-Acetaminophen | 18 | $254 | $14 |
| Omeprazole | 16 | $234 | $15 |
| Simvastatin | 14 | $233 | $17 |
| Hydrochlorothiazide | 23 | $231 | $10 |
| Pantoprazole | 23 | $198 | $9 |
| Furosemide | 45 | $191 | $4 |
| Carvedilol | 12 | $118 | $10 |
| Tramadol | 21 | $108 | $5 |
| Sertraline | 14 | $104 | $7 |
| Metoprolol | 18 | $101 | $6 |
| Azithromycin | 12 | $99 | $8 |
| Metformin | 16 | $94 | $6 |
| Alprazolam | 11 | $46 | $4 |
2013: 23 drugs
| Januvia | 16 | $4,109 | $257 |
| Advair Diskus | 12 | $3,697 | $308 |
| Zetia | 12 | $1,959 | $163 |
| Gabapentin | 19 | $1,605 | $84 |
| Proair Hfa | 16 | $920 | $57 |
| Fluticasone Propionate | 33 | $765 | $23 |
| Atorvastatin | 11 | $285 | $26 |
| Lisinopril | 32 | $278 | $9 |
| Levothyroxine | 19 | $274 | $14 |
| Pantoprazole | 21 | $270 | $13 |
| Amlodipine Besylate | 29 | $224 | $8 |
| Simvastatin | 18 | $222 | $12 |
| Omeprazole | 11 | $205 | $19 |
| Baclofen | 18 | $182 | $10 |
| Azithromycin | 17 | $169 | $10 |
| Hydrocodone-Acetaminophen | 14 | $139 | $10 |
| Metoprolol | 25 | $138 | $6 |
| Lisinopril-Hydrochlorothiazide | 11 | $121 | $11 |
| Sertraline | 14 | $120 | $9 |
| Tramadol | 15 | $119 | $8 |
| Furosemide | 16 | $93 | $6 |
| Alprazolam | 14 | $70 | $5 |
| Atenolol | 12 | $27 | $2 |
Money from drug and device companies
$15 in 2025
| 2025 | 1 | 1 | None | $15 |
| 2024 | 1 | 1 | None | $13 |
| 2023 | 6 | 6 | None | $132 |
| 2022 | 4 | 6 | None | $126 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Hologic Sales and Service | Aptima | $15 | 1 payment
|
See the published payment
| Hologic Sales and Service | Meals · 2025-05-15 | Aptima | $15 |
See earlier years (2024, 2023, 2022)
2024: $13
| ViiV Healthcare | Apretude | $13 | 1 payment
|
2023: $132
| Novo Nordisk | Rybelsus | $24 | 1 payment
|
| ViiV Healthcare | Apretude | $24 | 1 payment
|
| Alkermes | Vivitrol | $23 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $21 | 1 payment
|
| Pfizer | Prevnar 20 | $21 | 1 payment
|
| CooperSurgical | Paragard T 380a | $19 | 1 payment
|
2022: $126
| Dexcom | Dexcom G6 Transmitter | $61 | 3 payments
|
| Novo Nordisk | Rybelsus | $24 | 1 payment
|
| Abbott Laboratories | Freestyle Libre 2 | $22 | 1 payment
|
| Xeris Pharmaceuticals | Gvoke Pfs | $19 | 1 payment
|
Professional record
- NPI
- 1659548683
- Licence
- CA A123183, MI 4301089695California A123183: Current · expires 2028-08-31
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 40910 Fremont Blvd, Fremont, CA, 94538
- NPI first listed
- 2008-05-08
- NPI last updated
- 2026-09-14
- NPI record certified
- 2026-09-14
This is when the NPI record was last certified, not a medical board exam.